AQEMIA Reaches $100M Funding Milestone, Expands in London
Deal News | Dec 11, 2024 | Cathay Innovation
AQEMIA, a techbio company utilizing AI and quantum physics for drug discovery, announced securing a cumulative $100 million in funding. A new $38 million round was led by Cathay Innovation, supporting AQEMIA's expansion into London and preparations for clinical trials. The company is on track to employ its innovative platform for effective drug development, particularly in oncology. The partnership with Cathay Innovation is strategic, bringing expertise from international markets like the US and Asia, which aligns with AQEMIA's mission to transform molecule research and the pharma industry. The funding will be directed towards advancing AQEMIA's technology platform and global expansion, leveraging the UK's rich talent in life sciences and tech-bio sectors. With strong industry recognition and proven drug discovery platform, AQEMIA is poised for substantial impact in the field of medicine.
Sectors
- Healthcare & Pharmaceuticals
- Artificial Intelligence & Machine Learning
- Venture Capital & Private Equity
Geography
- United Kingdom – AQEMIA is establishing a presence in London as part of its global expansion plans.
- France – AQEMIA's headquarters and the location of becoming a prominent player in the techbio sector.
- Global – Cathay Innovation operates internationally and AQEMIA's ambitions extend to global markets, including US and Asia.
Industry
- Healthcare & Pharmaceuticals – The industry involves companies engaged in drug creation and innovations in medical treatments, relevant as AQEMIA focuses on developing medicines.
- Artificial Intelligence & Machine Learning – This industry involves the use of AI and ML technologies, key to AQEMIA's approach in drug discovery without relying on traditional experimental data.
- Venture Capital & Private Equity – Cathay Innovation's role as a venture capital firm investing in AQEMIA positions this article within the venture capital and private equity sector.
Financials
- $100 million – Total cumulative funding raised by AQEMIA.
- $38 million – Amount raised in the recent funding round led by Cathay Innovation.
- $140 million – Value of AQEMIA's collaboration with Sanofi, indicating the platform's potential.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| AQEMIA | Target Company | Company | A techbio firm using AI and quantum physics for innovative drug discovery. |
| Cathay Innovation | Leading Investor | Company | A venture capital firm leading the recent funding round for AQEMIA, providing strategic support. |
| Wendel | Investor | Company | Historical investor supporting AQEMIA's funding rounds. |
| Bpifrance Large Venture | Investor | Company | Another historical investor involved with AQEMIA. |
| Eurazeo | Investor | Company | Involved as a historical investor in AQEMIA. |
| Elaia | Investor | Company | Part of the historical investor group in AQEMIA. |
| Sanofi | Collaborator | Company | Pharmaceutical company collaborating with AQEMIA on a significant project. |